215 related articles for article (PubMed ID: 2904745)
21. A long-term study of doxazosin in the treatment of mild or moderate essential hypertension in general medical practice.
Manos J
Am Heart J; 1991 Jan; 121(1 Pt 2):346-51. PubMed ID: 1824659
[TBL] [Abstract][Full Text] [Related]
22. A comparative study of doxazosin versus atenolol in mild-to-moderate hypertension.
Giorgi G; Legramante JM; Fioravanti G; Paies G; Legramante A
Am Heart J; 1988 Dec; 116(6 Pt 2):1801-5. PubMed ID: 2904754
[TBL] [Abstract][Full Text] [Related]
23. Antihypertensive effects of doxazosin in systemic hypertension and comparison with terazosin.
Hayduk K; Schneider HT
Am J Cardiol; 1987 May; 59(14):95G-98G. PubMed ID: 2884860
[TBL] [Abstract][Full Text] [Related]
24. Clinical experience with doxazosin in general medical practice in New Zealand.
Maslowski AH
Am Heart J; 1991 Jan; 121(1 Pt 2):323-8. PubMed ID: 1824655
[TBL] [Abstract][Full Text] [Related]
25. A multicenter study of doxazosin in the treatment of patients with mild or moderate essential hypertension and concomitant intermittent claudication.
Catalano M; Libretti A
Am Heart J; 1991 Jan; 121(1 Pt 2):367-71. PubMed ID: 1824663
[TBL] [Abstract][Full Text] [Related]
26. Alpha-1 adrenoceptor blockade with doxazosin in hypertension: effects on blood pressure and lipoproteins.
Ames RP; Kiyasu JY
J Clin Pharmacol; 1989 Feb; 29(2):123-7. PubMed ID: 2565917
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of doxazosin in the treatment of patients with mild or moderate essential hypertension and elevated levels of cholesterol.
Taylor SH
Am Heart J; 1991 Jan; 121(1 Pt 2):362-6. PubMed ID: 1824662
[TBL] [Abstract][Full Text] [Related]
28. A double-blind parallel trial to assess the efficacy of doxazosin, atenolol and placebo in patients with mild to moderate systemic hypertension.
Nash DT; Schonfeld G; Reeves RL; Black H; Weidler DJ
Am J Cardiol; 1987 May; 59(14):87G-90G. PubMed ID: 2884859
[TBL] [Abstract][Full Text] [Related]
29. A multicenter study of doxazosin in the treatment of essential hypertension in France.
Bonnet G
Am Heart J; 1991 Jan; 121(1 Pt 2):335-40. PubMed ID: 1824657
[TBL] [Abstract][Full Text] [Related]
30. Serum lipid changes in a one-year, multicenter, double-blind comparison of doxazosin and atenolol for mild to moderate essential hypertension.
Frick MH; Cox DA; Himanen P; Huttunen M; Pitkäjärvi T; Pörsti P; Pöyhönen L; Pyykönen ML; Reinikainen P; Salmela P
Am J Cardiol; 1987 May; 59(14):61G-67G. PubMed ID: 2884854
[TBL] [Abstract][Full Text] [Related]
31. Long-term double-blind comparison of doxazosin and atenolol in patients with mild to moderate hypertension.
Lijnen P; Fagard R; Staessen J; Lissens W; Amery A
J Cardiovasc Pharmacol; 1989 Aug; 14(2):319-25. PubMed ID: 2476608
[TBL] [Abstract][Full Text] [Related]
32. Reduction of left ventricular hypertrophy after longterm antihypertensive treatment with doxazosin.
Agabiti-Rosei E; Muiesan ML; Rizzoni D; Zulli R; Calebich S; Beschi M; Castellano M; Muiesan G
J Hum Hypertens; 1992 Feb; 6(1):9-15. PubMed ID: 1349920
[TBL] [Abstract][Full Text] [Related]
33. Antihypertensive effect of doxazosin and atenolol in short- and long-term double-blind comparison.
Lijnen P; Fagard R; Staessen J; Amery A
Methods Find Exp Clin Pharmacol; 1990 Oct; 12(8):563-73. PubMed ID: 2151197
[TBL] [Abstract][Full Text] [Related]
34. Long-term effects of doxazosin and atenolol on serum lipids and blood pressure in hypertensive smokers.
Talseth T; Westlie L; Daae LN
J Hypertens Suppl; 1990 Sep; 8(5):S47-51. PubMed ID: 1981077
[TBL] [Abstract][Full Text] [Related]
35. Doxazosin: a study in a cohort of patients with hypertension in general practice--an interim report.
Langdon CG
Am Heart J; 1991 Jan; 121(1 Pt 2):268-73. PubMed ID: 1824649
[TBL] [Abstract][Full Text] [Related]
36. The addition of doxazosin to the therapeutic regimen of hypertensive patients inadequately controlled with other antihypertensive medications: a randomized, placebo-controlled study.
Black HR; Sollins JS; Garofalo JL
Am J Hypertens; 2000 May; 13(5 Pt 1):468-74. PubMed ID: 10826396
[TBL] [Abstract][Full Text] [Related]
37. Selective alpha 1 inhibition with doxazosin in hypertensive smokers and non-smokers: haemodynamic and metabolic effects.
Westheim A; Daae LN; Kierulf P; Brusletto B; Holme I; Syvertsen JO
J Hypertens Suppl; 1990 Sep; 8(5):S41-6. PubMed ID: 1981076
[TBL] [Abstract][Full Text] [Related]
38. Doxazosin: a newly developed, selective alpha 1-inhibitor in the management of patients with pheochromocytoma.
Miura Y; Yoshinaga K
Am Heart J; 1988 Dec; 116(6 Pt 2):1785-9. PubMed ID: 2904751
[TBL] [Abstract][Full Text] [Related]
39. Terazosin: ex vivo and in vitro platelet aggregation effects in patients with arterial hypertension.
Hernández Hernández R; Angeli-Greaves M; Carvajal AR; Guerrero Pajuelo J; Armas Padilla MC; Armas-Hernández MJ
Am J Hypertens; 1996 May; 9(5):437-44. PubMed ID: 8735174
[TBL] [Abstract][Full Text] [Related]
40. Antihypertensive effect of doxazosin in hypertensive patients: comparison with atenolol.
Baez MA; Garg DC; Jallad NS; Weidler DJ
Br J Clin Pharmacol; 1986; 21 Suppl 1(Suppl 1):63S-67S. PubMed ID: 2939869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
